HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

MRNA — Moderna Inc.

MRNA (Moderna Inc.) stock: $254.19, $101.48B market cap, $7.98B cash, $94.10B EV, $112.10B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We currently have three commercial products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory syncytial virus (RSV)). mNEXSPIKE, which we launched commercially in the third quarter of 2025, is now our leading product in the U.S. retail channel.

Source: 10-K FY2025 via SEC EDGAR

Share price
$254.19
Market cap
$101,481.8M
Cash
$7,976.0M
Enterprise value
$94,096.8M

Balance sheet

Cash$7,976.0M
Debt$591.0M
Net cash$7,385.0M
Enterprise value$94,096.8M
Basic shares404.6M shares
Fully diluted shares441.0M shares
Fully diluted market cap$112,097.8M
Cash per share$19.71
Quarterly burn$526.0M
Cash runway13.1 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common
399.0M
Pre-funded warrants
0.0M
Options
42.0M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
441.0M

Cap table as of 2026-06-30.

Price history

Loading MRNA daily closes…

Loading price history…

Next catalyst

mRNA-3927 · Est. Nov 7, 2026 · guidance midpoint · guided Now

Recently reported

Intismeran autogene Phase 3 Positive · 2026-10-22
IIB-IV · melanoma
Primary: Recurrence-free survival (RFS), defined as the time from randomization to any disease recurrence (local, locoregional, regional or distant) as assessed by the investigator, or death due to any cause — intismeran plus KEYTRUDA reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45-0.75]; two-sided p<0.001) compared to KEYTRUDA alone; two-year RFS rate 82.2% (95% CI, 79.3%-84.8%) vs 70.0% (95% CI, 65.0%-74.5%); median RFS not reached for either arm
· Distant metastasis-free survival (DMFS): reduced risk of distant metastasis or death by 38% (HR=0.62 [95% CI, 0.45-0.85]; two-sided p=0.002); two-year DMFS rate 88.5% (95% CI, 86.0%-90.6%) vs 80.2% (95% CI, 75.6%-84.0%); median DMFS not reached for either arm
· Median follow-up 24.6 months at the primary pre-specified analysis (intention-to-treat); trial enrolled 1,137 patients with completely resected stage IIB-IV melanoma, randomized 2:1
· Modified intent-to-treat sensitivity analysis: RFS HR=0.51 [95% CI, 0.39-0.67], DMFS HR=0.55 [95% CI, 0.40-0.77]
· Post-immunization (after six months) sensitivity analysis: RFS HR=0.42 [95% CI, 0.30-0.58], DMFS HR=0.50 [95% CI, 0.34-0.73]; first six months RFS HR=0.99 [95% CI, 0.66-1.49], DMFS HR=1.01 [95% CI, 0.58-1.79]
· Overall survival data are not yet mature, but a favorable trend in OS with intismeran plus KEYTRUDA has been observed; study remains ongoing
Safety: Safety profile generally consistent with previously reported studies, no new safety signals; treatment-related adverse events 95.8% (723 of 755) vs 90.0% (342 of 380), Grade 3-5 TRAEs 14.2% vs 13.4%; most common AEs in the combination arm were pyrexia (52.2%), injection site pain (51.0%) and fatigue (38.5%)
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego